Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. METHODS: We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology - Self Report (QIDS-SR-16), obtained at treatment visits, determined secondary outcomes, including remission (a score of 5 or less at exit) and response (a reduction of 50 percent or more on baseline scores). RESULTS: Remission rates as assessed by the HRSD-17 and the QIDS-SR-16, respectively, were 21.3 percent and 25.5 percent for sustained-release bupropion, 17.6 percent and 26.6 percent for sertraline, and 24.8 percent and 25.0 percent for extended-release venlafaxine. QIDS-SR-16 response rates were 26.1 percent for sustained-release bupropion, 26.7 percent for sertraline, and 28.2 percent for extended-release venlafaxine. These treatments did not differ significantly with respect to outcomes, tolerability, or adverse events. CONCLUSIONS: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant. Any one of the medications in the study provided a reasonable second-step choice for patients with depression. (ClinicalTrials.gov number, NCT00021528.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A subset of those suffering from Major Depressive Disorder (MDD) achieve remission with antidepressant medication (ADM)1.”
From The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse (2020) · cites this paper as [1]
In the citing paper
“about onethird receive no benefit from two or more pharmacologic treatments (Rush et al., 2006;Trivedi et al., 2006).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Rush et al., 2006
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Schafer, J. L. (1999) · Statistical Methods in Medical Research · doi:10.1177/096228029900800102 · Cited by 3,949
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Self-citationCUMULATIVE ILLNESS RATING SCALE
LINN, B. S., LINN, M. W., & GUREL, L. (1968) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1968.tb02103.x · Cited by 2,304
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationAgency for Health Care Policy and Research
Eisenberg, J. M. (1999) · Medical Care · doi:10.1097/00005650-199903000-00001 · Cited by 1,369
Sequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citation
Research works printed but not linked: 4
- Agency for Health Care Policy and Research. Depression in primary care. Vol. 2. Treatment of major depression. Rockville, Md.: Department of Health and Human Services, 1993. (AHCPR publication no. 93-0551.)
- Fava M, 2000, J Clin Psychiatry, 61, 10
- Joffe RT, 1996, J Clin Psychiatry, 57, 114
- Fava M, 2003, Ann Clin Psychiatry, 15, 17, 10.3109/10401230309085666 · doi:10.3109/10401230309085666 · Paper page
Cited by
Items 201–300 of 999
Perlis, R. H., Patrick, A., Smoller, J. W., & Wang, P. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.50 · Cited by 83
How (Not What) to Prescribe: Nonpharmacologic Aspects of Psychopharmacology
Mintz, D. L., & Flynn, D. F. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.009 · Cited by 82
Finding factors that predict treatment-resistant depression: results of a cohort study
Cepeda, M. S., Reps, J., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22774 · Cited by 80
“When more treatments are needed, higher relapse rates are expected (Rush et al., 2006), and when a patient does not respond to antidepressant This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in…”
BackgroundFolate and Unipolar Depression
Morris, D. W., Trivedi, M. H., & Rush, A. J. (2008) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2007.0663 · Cited by 80
Self-citationMüller, D. J., Kekin, I., Kao, A. C. C., & Brandl, E. J. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.838944 · Cited by 80
“Similar to APs, treatment with ADs will only show symptom improvement in 35 – 45% of patients and a large portion of patients will not achieve complete symptom remission (Adli et al., 2006; Rush et al., 2006).”
MethodJha, M. K., Minhajuddin, A., Gadad, B. S., Greer, T. L., Mayes, T. L., & Trivedi, M. H. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.07.005 · Cited by 79
Self-citationHird, E. J., Slanina-Davies, A., Lewis, G., Hamer, M., & Roiser, J. P. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02922-y · Cited by 79
“Depression is also dif fi cult to treat: fewer than half of people respond to selective serotonin reuptake inhibitors, with only around one-third remitting from their fi rst pharmacological treatment [3] and still fewer remit after switching to a second treatment [4].”
Altar, C. A., Carhart, J., Allen, J. D., Hall-Flavin, D., Winner, J., & Dechairo, B. (2015) · Complex Psychiatry · doi:10.1159/000430915 · Cited by 79
Weeks, H. R., Tadler, S. C., Smith, K. W., Iacob, E., Saccoman, M., White, A. T., Landvatter, J. D., Chelune, G. J., Suchy, Y., Clark, E., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069809 · Cited by 79
“For nonresponders to the first agent, the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial showed that the remission rate decreased from 37% to 13% as successive medication alternatives were tried [1] .”
BackgroundPharmacotherapy of Mood Disorders
Thase, M. E., & Denko, T. (2008) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.2.022305.095301 · Cited by 79
Self-citationHurt, R. T., Stephenson, C. R., Gilman, E. A., Aakre, C. A., Croghan, I. T., Mundi, M. S., Ghosh, K., & Edakkanambeth Varayil, J. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251332215 · Cited by 78
Neuropsychologic effects of neuromodulation techniques for treatment-resistant depression: A review
Moreines, J. L., McClintock, S. M., & Holtzheimer, P. E. (2011) · Brain Stimulation · doi:10.1016/j.brs.2010.01.005 · Cited by 78
“Up to half of patients with Major Depressive Disorder (MDD) do not respond to first-line antidepressant treatment (1), and one third do not respond to two or more treatments (2,3).”
Moffa, A. H., Brunoni, A. R., Fregni, F., Palm, U., Padberg, F., Blumberger, D. M., Daskalakis, Z. J., Bennabi, D., Haffen, É., Alonzo, A., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.021 · Cited by 82
Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients
Bhattacharyya, S., Ahmed, A. T., Arnold, M., Liu, D., Luo, C., Zhu, H., Mahmoudiandehkordi, S., Neavin, D., Louie, G., Dunlop, B. W., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0507-5 · Cited by 77
Self-citationBrain eicosapentaenoic acid metabolism as a lead for novel therapeutics in major depression
Bazinet, R. P., Metherel, A. H., Chen, C. T., Shaikh, S. R., Nadjar, A., Joffre, C., & Layé, S. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.07.001 · Cited by 83
Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
“The SSRI citalopram was also associated with significant and clinically relevant improvements on the MADRS, supporting the validity and assay sensitivity of this trial.”
BackgroundInfluentialMoulton, C. D., Hopkins, C. W. P., Ismail, K., & Stahl, D. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.05.010 · Cited by 77
Voigt, J., Carpenter, L., & Leuchter, A. (2019) · BMC Psychiatry · doi:10.1186/s12888-018-1989-z · Cited by 77
Restoring melancholia in the classification of mood disorders
Taylor, M. A., & Fink, M. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.05.023 · Cited by 84
“The protocols for the STAR⁎D (Rush et al., 2006) and the two multi-center ECT studies (Kellner et al.”
MethodPerlis, R. H., Fijal, B. A., Adams, D. H., Sutton, V. K., Trivedi, M. H., & Houston, J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.002 · Cited by 84
Self-citationWhat predicts attrition in second step medication treatments for depression?: a STAR*D Report
Warden, D., Rush, A. J., Wisniewski, S. R., Lesser, I. M., Kornstein, S. G., Balasubramani, G. K., Thase, M. E., Preskorn, S. H., Nierenberg, A. A., Young, E. A., et al. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009073 · Cited by 77
“…Portions of this paper were presented in poster form at the International Society for Affective Disorders (ISAD), 4th Biennial Conference, Capetown, South Africa, March 2008. symptoms) and remission is associated with improved functioning andprognosis (Hirschfeld et al., 2002;Rush et al., 2006b).”
InfluentialSelf-citationTreatment strategies to improve and sustain remission in major depressive disorder
Madhukar H., T., & Ella J., D. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/mhtrivedi · Cited by 75
“However, there is now evidence that switching from one SSRI to another SSRI may be a reasonable strategy.(4) Furthermore, switching from a medication to a depression-focused psychotherapy, or vice versa, appears to produce comparable outcomes.”
BackgroundSelf-citationPapakostas, G. I., Trivedi, M. H., Alpert, J. E., Seifert, C. A., Krishen, A., Goodale, E. P., & Tucker, V. L. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.05.012 · Cited by 82
Self-citationModulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression
Eyre, H., Lavretsky, H., Kartika, J., Qassim, A., & Baune, B. (2016) · Pharmacopsychiatry · doi:10.1055/s-0042-103159 · Cited by 73
Schneeweiss, S., Patrick, A. R., Solomon, D. H., Mehta, J., Dormuth, C., Miller, M., Lee, J. C., & Wang, P. S. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.39 · Cited by 74
Inflammation and depression but where does the inflammation come from?
Halaris, A. E. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000531 · Cited by 80
Bschor, T., & Baethge, C. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01458.x · Cited by 75
“Due to the design of the STAR*D study, different switching or augmenting strategies were compared with each other, but not with the continuation of the initial antidepressant treatment (30, 31).”
MethodTreatment-Resistant Depression: Critique of Current Approaches
Wijeratne, C., & Sachdev, P. (2008) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670802277206 · Cited by 74
“whether they were switched to another SSRI (sertraline), a SNRI (venlafaxine), or an NDRI (bupropion) antidepressant [34].”
BackgroundRuhé, H. G., Booij, J., Weert, H. C. V., Reitsma, J. B., Fransen, E. J. F., Michel, M. C., & Schene, A. H. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.148 · Cited by 73
“Switching (Rush et al, 2006) and augmentation (Trivedi et al, 2006a) have recently been evaluated.”
BackgroundPersonalized Treatment of Alcohol Dependence
Kranzler, H. R., & McKay, J. R. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0296-5 · Cited by 73
Kantrowitz, J., Citrome, L., & Javitt, D. (2009) · CNS Drugs · doi:10.2165/00023210-200923080-00005 · Cited by 72
Emerging targets for antidepressant therapies
Rakofsky, J. J., Holtzheimer, P. E., & Nemeroff, C. B. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.617 · Cited by 72
“Despite adequate care with currently available treatments, up to 70% of depressed patients have residual symptoms [3], and, even with more aggressive therapies, 20% or more may show only a limited response [4].”
BackgroundAdli, M., Wiethoff, K., Baghai, T. C., Fisher, R., Seemüller, F., Laakmann, G., Brieger, P., Cordes, J., Malevani, J., Laux, G., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx043 · Cited by 71
“The aim of the German Algorithm Project therefore was to evaluate the effects of treatment algorithms in the care of inpatients with MDD. Results show that a stepwise treatment regimen with critical decision points at the end of each treatment step based on standardized measurements of response and an algorithm-guided…”
BackgroundMethodInfluentialPharmacological interventions for treatment-resistant depression in adults
Davies, P., Ijaz, S., Williams, C. J., Kessler, D., Lewis, G., & Wiles, N. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010557.pub2 · Cited by 73
What Are the Implications of the STAR*D Trial for Primary Care?: A Review and Synthesis
Huynh, N. N., & McIntyre, R. S. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0201 · Cited by 72
“2 mg/d) treatment.(2) There were no statistically significant differences between groups in rates of remission and overall tolerability burden.”
BackgroundRollman, B. L., Belnap, B. H., LeMenager, M. S., Mazumdar, S., Schulberg, H. C., & Reynolds, C. F. (2009) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181970c1c · Cited by 72
“As in PROSPECT and STAR*D, we recommended that patients who responded poorly or were unable to tolerate citalopram switch to another SSRI, an effective strategy in approximately 20% to 50% of patients who failed an initial SSRI trial (56,65).”
MethodInfluentialPersonality, stressful life events, and treatment response in major depression.
Bulmash, E., Harkness, K. L., Stewart, J. G., & Bagby, R. M. (2009) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0017149 · Cited by 71
Self-citationIs There Anything Really Novel on the Antidepressant Horizon?
Murrough, J. W., & Charney, D. S. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0321-8 · Cited by 69
Treatment strategies to improve and sustain remission in major depressive disorder.
Trivedi, M. H., & Daly, E. (2008) · Europe PMC (PubMed Central) · Cited by 70
Self-citationReed, C. C., Monz, B. U., David, P., Gandhi, P., Bauer, M., Dantchev, N., Demyttenaere, K., Garcia-Cebrian, A., Grassi, L. G., Quail, D., et al. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.05.021 · Cited by 75
Allopregnanolone in mood disorders: Mechanism and therapeutic development
Chen, S., Gao, L., Li, X., & Ye, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105682 · Cited by 75
Ethnicity/Race and Outcome in the Treatment of Depression: Results From STAR*D
Lesser, I. M., Castro, D. B., Gaynes, B. N., Gonzalez, J. M., Rush, A. J., Alpert, J. E., Trivedi, M. H., Luther, J. F., & Wisniewski, S. R. (2007) · Medical Care · doi:10.1097/mlr.0b013e3181271462 · Cited by 70
Self-citationAssociation of Depressive Symptoms with Hippocampal Volume in 1936 Adults
Brown, E. S., Hughes, C. W., McColl, R. W., Peshock, R. M., King, K. S., & Rush, A. J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.271 · Cited by 74
“…and is strongly associated with scores on clinician-rated depression instruments (Rush et al, 2003) and structured diagnostic interviews (Bernstein et al, 2009; Doraiswamy et al, 2010), and has been used in large clinical studies (Kessler et al, 2003; Rush et al, 2006b; Trivedi et al, 2006).”
BackgroundMethodSelf-citationScherrer, J. F., Chrusciel, T., Garfield, L. D., Freedland, K. E., Carney, R. M., Hauptman, P. J., Bucholz, K. K., Owen, R., & Lustman, P. J. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096479 · Cited by 68
The Impact of Residual Symptoms in Major Depression
Israel, J. A. (2010) · Pharmaceuticals · doi:10.3390/ph3082426 · Cited by 67
First‑line pharmacotherapies for depression – what is the best choice?
Koenig, A. M., & Thase, M. E. (2009) · Polish Archives of Internal Medicine · doi:10.20452/pamw.743 · Cited by 67
Self-citationExercise in the treatment of depression
Greer, T. L., & Trivedi, M. H. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0071-4 · Cited by 77
Self-citationJobes, D., Rudd, M., Overholser, J., & Joiner, T. E. (2008) · Professional Psychology Research and Practice · doi:10.1037/a0012896 · Cited by 59
“Beyond considerations of suicide risk, it is interesting to note that although medications appear to work for many patients, they do not work for many others, and length of treatment is an important consideration (e.g., Rush et al., 2006).”
BackgroundHewett, K., Gee, M. D., Krishen, A., Wunderlich, H.-P., Le Clus, A., Evoniuk, G., & Modell, J. G. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109106953 · Cited by 64
“…1997; Kennedy et al., 2006; Little et al., 2005; Thase et al., 2006; Weihs et al., 2000), nor with a large, collaborative study (STAR*D) that demonstrated similar response rates for bupropion SR and venlafaxine XR in patients who had failed to respond to citalopram treatment (Rush et al., 2006).”
ResultPerahia, D. G. S., Quail, D., Desaiah, D., Montejo, A. L., & Schatzberg, A. F. (2009) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.07.001 · Cited by 64
“As evidenced by numerous studies including the recent STAR-D study (Rush et al., 2006), however, suboptimal response to the initial antidepressant agent is common, and in the event of suboptimal treatment response, there are a number of possible approaches that can be employed including increasing the dose (e.”
ResultIdentifying Difficult-to-Treat Depression: Differential Diagnosis, Subtypes, and Comorbidities
Gaynes, B. N. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.8133su1c.02 · Cited by 64
Antidepressant monotherapy: A claims database analysis of treatment changes and treatment duration
Milea, D., Guelfucci, F., Bent‐Ennakhil, N., Toumi, M., & Auray, J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.11.011 · Cited by 70
Vagus nerve stimulation for the treatment of depression and other neuropsychiatric disorders
George, M. S., Nahas, Z., Borckardt, J. J., Anderson, B., Burns, C., Kose, S., & Short, E. B. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.1.63 · Cited by 61
Rush, A. J., South, C. C., Jain, S. B., Agha, R. S., Zhang, M., Shrestha, S., Khan, Z., Hassan, M., & Trivedi, M. H. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s305331 · Cited by 66
“Patients without a response (at least a 50% reduction in baseline QIDS-C) and those with a response that was short of remission were encouraged to enter the second treatment step, which could entail either a switch in treatment 42 or an augmentation of the initial treatment.”
Self-citationHowland, R. H., Wilson, M. G., Kornstein, S. G., Clayton, A. H., Trivedi, M. H., Wohlreich, M. M., & Fava, M. (2008) · Annals of Clinical Psychiatry · doi:10.1080/10401230802437639 · Cited by 62
Self-citationKozel, F. A., Rao, U., Lu, H., Nakonezny, P. A., Grannemann, B., McGregor, T., Croarkin, P. E., Mapes, K. S., Tamminga, C. A., & Trivedi, M. H. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00007 · Cited by 61
“…outcome measure because of its ability to be easily integrated into clinical practice and established psychometric properties (Trivedi et al., 2004; Rush et al., 2006a,b). mrI ScannIng Participants were placed in the MRI with hearing protection and foam padding around their head in order to reduce…”
BackgroundMethodInfluentialSelf-citationA critical review of pharmacotherapy for major depressive disorder.
Dupuy, J. M., Ostacher, M. J., Huffman, J., Perlis, R. H., & Nierenberg, A. A. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000083 · Cited by 61
Self-citationJohnson, D., Letchumanan, V., Thum, C. C., Thurairajasingam, S., & Lee, L. (2023) · Nutrients · doi:10.3390/nu15061382 · Cited by 78
for the SUN☺D Investigators, Kato, T., Furukawa, T. A., Mantani, A., Kurata, K., Kubouchi, H., Hirota, S., Sato, H., Sugishita, K., Chino, B., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1096-5 · Cited by 61
Optogenetics enlightens neuroscience drug discovery
Song, C., & Knöpfel, T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.15 · Cited by 70
Clinical Implications of the STAR*D Trial
Rush, A. J., & Jain, S. K. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_153 · Cited by 65
Self-citationZeni, A. L. B., Zomkowski, A. D. E., Maraschin, M., Rodrigues, A. L. S., & Tasca, C. I. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.08.020 · Cited by 60
“Additionally, they are hindered by adverse side effects and are slow to produce beneficial effects (Rush et al., 2006).”
BackgroundBrainstem Aminergic Nuclei and Late-Life Depressive Symptoms
Wilson, R. S., Nag, S., Boyle, P. A., Hizel, L. P., Yu, L., Buchman, A. S., Shah, R. C., Schneider, J. A., Arnold, S. E., & Bennett, D. A. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2224 · Cited by 60
Reutfors, J., Andersson, T., Tanskanen, A. J., DiBernardo, A., Li, G., Brandt, L., & Brenner, P. (2019) · Archives of Suicide Research · doi:10.1080/13811118.2019.1691692 · Cited by 77
Papakostas, G. I., Trivedi, M. H., Shelton, R. C., Iosifescu, D. V., Thase, M. E., Jha, M. K., Mathew, S. J., DeBattista, C., Dokucu, M. E., Brawman‐Mintzer, O., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02468-x · Cited by 73
“…to venlafaxine XR/duloxetine in ASCERTAIN is similar to those observed in the level 2 of Sequenced Treatment Alternatives to Relieve Depression [30], where individuals with MDD were switched to venlafaxine after inadequate improvement on treatment with citalopram (28.2% and 25.0%,…”
ResultInfluentialSelf-citationHarrison, E. L., & Baune, B. T. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.31 · Cited by 58
Sequenced Treatment Alternatives to Relieve Depression (STAR*D): Part 1: Study Design
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20080901-06 · Cited by 59
Polypharmacy With Second-Generation Antipsychotics: A Review of Evidence
Pandurangi, A., & Dalkiliç, A. (2008) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000341890.05383.45 · Cited by 65
Hong, R. H., Murphy, J. K., Michalak, E. E., Chakrabarty, T., Wang, Z., Parikh, S., Culpepper, L., Yatham, L. N., Lam, R. W., & Chen, J. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s283731 · Cited by 55
Clinical issues in considering vagus nerve stimulation for treatment-resistant depression
Rush, A. J., & Siefert, S. E. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.04.015 · Cited by 63
Self-citationmTORC1-dependent protein synthesis underlying rapid antidepressant effect requires GABABR signaling
Workman, E. R., Niere, F., & Raab‐Graham, K. F. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.037 · Cited by 59
“%) and relies on lengthy use of antidepressants for therapy (Kessler et al., 2003; Murrough, 2012; Rush et al., 2011, 2006).”
BackgroundBentley, S. M., Pagalilauan, G. L., & Simpson, S. A. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.013 · Cited by 81
“After failure to respond to citalopram, 25% of subjects experienced remission with switching medications to another SSRI or to a different class of medications (venlafaxine, bupropion).(125) Alternatively, 30% of subjects experienced remission with augmentation of the SSRI with bupropion or buspirone (although buspiro…”
BackgroundPigott, T. A., Prakash, A., Arnold, L. M., Aaronson, S. T., Mallinckrodt, C. H., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x188107 · Cited by 58
Hewett, K., Chrzanowski, W., Schmitz, M., Savela, A., Milanova, V, Gee, M., Krishen, A., Millen, L., Leary, M., & Modell, J. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089602 · Cited by 57
Dopamine agonist‐responsive depression
Hori, H., & Kunugi, H. (2013) · Psychogeriatrics · doi:10.1111/psyg.12014 · Cited by 57
Ramsberg, J., Asseburg, C., & Henriksson, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042003 · Cited by 57
“The average time until remission and relapse as well as the effect of second and third line treatment were taken from a large naturalistic outcomes study of sequenced treatment of depression in primary care [18–20].”
BackgroundFink, M., & Taylor, M. A. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.00958.x · Cited by 68
“A cogent example is the evaluation of antidepressants in the STAR*D study (2).”
BackgroundMidline and right frontal brain function as a physiologic biomarker of remission in major depression
Cook, I. A., Hunter, A. M., Abrams, M., Siegman, B., & Leuchter, A. F. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2009.04.011 · Cited by 60
“…monitoring, and a 12-week period to exhibit improvement (Trivedi et al., 2006a); at the end of a second level of randomized treatment, the total fraction of remitted subjectswas approximately 50%, leavingalmost half of subjects with incomplete responses (Rush et al., 2006; Trivedi et al., 2006b).”
BackgroundClinical Inertia in Depression Treatment
Henke, R. M., Zaslavsky, A. M., McGuire, T. G., Ayanian, J. Z., & Rubenstein, L. V. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819a5da0 · Cited by 55
The Use of ECT and MST in treating depression
Allan, C. L., & Ebmeier, K. P. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.614223 · Cited by 59
“For those patients who do not respond to medication initially, the chance of successful remission is reduced when a second or third drug is tried (Rush et al., 2006; Trivedi et al., 2006a, 2006b).”
BackgroundUnifying treatments for depression: an application of the free energy principle
Chekroud, A. M. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00153 · Cited by 55
Żurawek, D., & Turecki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111312 · Cited by 72
“Although drugs which modulate serotonergic and/or noradrenergic neurotransmitter systems show effective antidepressant action [9], a significant proportion of individuals with depressive disorders do not respond to a given antidepressant treatment [10,11].”
BackgroundBlier, P., & Blondeau, C. (2011) · Journal of Affective Disorders · doi:10.1016/s0165-0327(11)70003-9 · Cited by 63
A phase-specific neuroimmune model of clinical depression
Eyre, H. A., Stuart, M. J., & Baune, B. T. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.011 · Cited by 60
“(Trivedi et al., 2006), and nearly onethird will not achieve remission following several treatment steps (Rush et al., 2006a, 2006b).”
BackgroundInfluentialPrediction of antidepressant treatment response from gray matter volume across diagnostic categories
Sämann, P. G., Höhn, D., Chechko, N., Kloiber, S., Lucae, S., Ising, M., Holsboer, F., & Czisch, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.07.004 · Cited by 55
“The importance of achieving remission has also been highlighted by the Sequenced Treatment Alternatives to Relieve Depression (STARD) trial that studied outpatients demonstrating that after failed first treatment with citalopram the likelihood to achieve remission in subsequent trials using other antidepressants alone…”
BackgroundThe Mistreatment of Major Depressive Disorder
Paris, J. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405900306 · Cited by 60
Workman, E. R., Haddick, P. C. G., Bush, K., Dilly, G. A., Niere, F., Zemelman, B. V., & Raab-Graham, K. F. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.165 · Cited by 54
Fang, Y., Yuan, C., Xu, Y., Chen, J., Wu, Z., Cao, L., Yi, Z., Hong, W., Wang, Y., Jiang, K., et al. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181e7784f · Cited by 54
“6%, respectively.(23) Meanwhile, Fava et al(24) found that in patients who failed an adequate dosage and duration of SSRI treatment, the response rate to mirtazapine treatment was 48%.”
BackgroundResultSelf-citationSchmidt, M. E., Kezic, I., Popova, V., Melkote, R., van der Ark, P. D., Pemberton, D. J., Mareels, G., Canuso, C. M., Fava, M., & Drevets, W. C. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01862-x · Cited by 56
“While switching antidepressants and using adjunctive treatments may improve response, almost 40% of patients remain symptomatic and fail to achieve remission despite multiple treatment trials [9, 10].”
BackgroundTreatment of sleep dysfunction and psychiatric disorders
Becker, P. M., & Sattar, M. T. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0039-z · Cited by 54
Emerging antidepressants to treat major depressive disorder
Block, S. G., & Nemeroff, C. B. (2014) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2014.09.001 · Cited by 61
“switching to a SNRI (venlafaxine), and the STAR*D trial showed a 7% advantage when using a SNRI; however neither of these differences were statistically significant (Baldomero et al., 2005; Rush et al., 2006).”
MethodHitti, F. L., Yang, A. I., Cristancho, M. A., & Baltuch, G. H. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092796 · Cited by 57
Paroxetine: current status in psychiatry
Pae, C.-U., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.107 · Cited by 53
Kozel, F. A., Johnson, K. A., Nahas, Z., Nakonezny, P. A., Morgan, P. S., Anderson, B. S., Kose, S., Li, X., Lim, K. O., Trivedi, M. H., et al. (2011) · The Journal of ECT · doi:10.1097/yct.0b013e3181e6317d · Cited by 51
“R ecent reports have highlighted that, although there are a number of effective treatments for depression, a significant portion of patients still fail to improve with standard medication therapies.(1,2) New treatments are actively being investigated to treat this devastating syndrome.”
BackgroundSelf-citationLin, E. H. B. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.009 · Cited by 60
Lesion network localization of depression in multiple sclerosis
Siddiqi, S., Kletenik, I., Anderson, M. C., Cavallari, M., Chitnis, T., Glanz, B. I., Khalil, S., Palotai, M., Bakshi, R., Guttmann, C. R. G., et al. (2023) · Nature Mental Health · doi:10.1038/s44220-022-00002-y · Cited by 55
Treatment-resistant depression: recent developments and future directions
Mathew, S. J. (2008) · Depression and Anxiety · doi:10.1002/da.20540 · Cited by 51
“higher than approved doses;([4]) (3) most critically, the infrequent implementation of measurement-based care([5]) in clinical practice obstructs the accurate determination of response to previous therapies.”
BackgroundMethodCepeda, M. S., Reps, J., Fife, D., Blacketer, C., Stang, P., & Ryan, P. (2018) · Depression and Anxiety · doi:10.1002/da.22705 · Cited by 50
“Depression is associated with substantial morbidity, heathcare cost, mortality and family burden (Kessler, 2012; Rush et al., 2006b), and affects 5% to 8% of the adult US population annually (Blazer, Kessler, McGonagle, & Swartz, 1994; Cepeda, Stang, &Makadia, 2016; Kessler, Chiu, Demler,…”
BackgroundInfluentialThe Eph receptor A4 plays a role in demyelination and depression-related behavior
Li, Y., Su, P., Chen, Y., Nie, J., Yuan, T., Wong, A. H. C., & Liu, F. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152187 · Cited by 56
“Many patients are refractory to current antidepressant medications (4, 5), which, despite significant improvements over older drugs, can still cause intolerable side effects (6, 7).”
Background
Metadata
- Authors
- Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., Shores-Wilson, K., Niederehe, G., & Fava, M.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- University of Pittsburgh (US)
- New York State Psychiatric Institute (US)
- Massachusetts General Hospital (US)
- National Institute of Mental Health (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-03-23
- Volume
- 354
- Issue
- 12
- Pages
- 1231-1242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140787893
- Cited by
- 1,033
- References
- 44
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 30 · 2023: 30 · 2022: 28 · 2021: 46 · 2020: 43 · 2019: 54 · 2018: 51 · 2017: 35 · 2016: 42 · 2015: 45 · 2014: 46 · 2013: 45 · 2012: 43
- FWCI
- 66.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh90003-26-0-0)
- National Institute of Mental Health (N01‐MH‐90003)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- major depressive disorder, antidepressant switching, bupropion, sertraline, venlafaxine, treatment-resistant depression, symptom remission, antidepressant response, outpatients
- MeSH terms
- Venlafaxine Hydrochloride, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Female, Humans, Male, Remission Induction, Time Factors, Bupropion, Treatment Failure, Selective Serotonin Reuptake Inhibitors, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.